CVT-3127, with the chemical name Ethyl 1-(6-amino-9-β-D-ribofuranosyl-9H-purin-2-yl)-1H-pyrazole-4-carboxylate, is a synthetic nucleoside analog. Its structure is based on a purine core (adenine derivative) modified at the 2-position with a pyrazole-4-carboxylate ethyl ester group and linked to a β-D-ribofuranosyl sugar moiety. This specific modification makes it a valuable chemical entity in medicinal chemistry research. This compound is primarily known as a potent and selective antagonist of the adenosine A2A receptor. Adenosine receptors are G-protein-coupled receptors involved in various physiological processes, including modulation of neurotransmitter release, immune response, and cardiovascular function. As an A2A receptor antagonist, CVT-3127 has been extensively used as a pharmacological tool in preclinical research to study the role of this receptor subtype in conditions such as Parkinson's disease, inflammation, and cancer immunotherapy. Its high selectivity over other adenosine receptor subtypes (A1, A2B, A3) is a key feature for mechanistic studies. While not a marketed drug itself, CVT-3127 serves as a crucial research chemical and a potential lead compound or intermediate for the development of therapeutic agents targeting the adenosine A2A pathway. Its structure embodies characteristics of both nucleosides and heterocyclic compounds, placing it at the intersection of biochemistry and synthetic medicinal chemistry.